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AbstrACt
Objectives In Barbados, high case fatality rates have 
been reported after myocardial infarction (MI) with higher 
rates in women than men. To explore this inequality, we 
examined documented pharmacological interventions 
for ST-segment elevated myocardial infarction (STEMI), 
non-STEMI (NSTEMI) and unstable and chronic angina in 
women and men.
Design Prospective cohort registry data for STEMI and 
NSTEMI and retrospective chart review for unstable and 
chronic angina.
setting Tertiary care (acute coronary syndromes) and 
primary care (chronic angina) centres in Barbados.
Participants For the years 2009–2016, a total of 1018 
patients with STEMI or NSTEMI were identified via the 
prospective study. For unstable and chronic angina, 136 
and 272 notes were reviewed respectively for the years 
2010–2014.
Outcome measures The proportions of patients 
prescribed recommended medication during the first 
24 hours after an acute event, at discharge and for 
chronic care were calculated. Prescribed proportions were 
analysed by gender after adjustment for age.
results Between 2009 and 2016, for the acute 
management of patients with NSTEMI and STEMI, 
only two (aspirin and clopidogrel) of six drugs had 
documented prescription rates of 80% or more. 
Patients with STEMI (n=552) had higher prescription 
rates than NSTEMI (n=466), with gender differences 
being more pronounced in the former. Among patients 
with STEMI, after adjustment for age, diabetes, 
hypertension and smoking, men were more likely to 
receive fibrinolytics acutely, OR 2.28 (95% CI 1.24 
to 4.21). Compared with men, a higher proportion 
of women were discharged on all recommended 
treatments; this was only statistically significant 
for beta-blockers: age-adjusted OR 1.87 (95% CI 
1.16 to 3.00). There were no statistically significant 
differences in documented prescription of drugs for 
chronic angina.
Conclusion Following acute MI in Barbados, the 
proportion of patients with documented recommended 
treatment is relatively low. Although women were less 
likely to receive appropriate acute care than men, by 
discharge gender differences were reversed.
IntrODuCtIOn 
Coronary heart disease (CHD) is associ-
ated with high mortality prehospital, in-hos-
pital and in the weeks following hospital 
discharge.1–3 The risk of death and future 
events for patients experiencing an acute 
coronary syndrome (ACS) can be reduced 
substantially through the timely introduc-
tion of treatment.4 Despite this, adherence to 
guidelines by physicians has not always been 
adequate.5 6 
Globally, gender differences exist with 
respect to ACS outcomes and treatment.7 
In Barbados, unpublished data indicate that 
in-hospital acute myocardial infarction (MI) 
case fatality rate (2013) was 40.8% (95% CI 
32.0 to 51.2) with higher rates in women 
after age adjustment (risk ratio=1.18; 95% CI 
1.02 to 1.37).8 The 2016 annual report of 
the national registry of Barbados indicated 
that the age-standardised mortality rate for 
MI was 56.2 per 100 000 population.9 Debate 
exists internationally related to whether the 
difference in outcomes is due to treatment 
strengths and limitations of this study
 ► Population-based prospectively collected data for all 
ST-segment elevated myocardial infarctions (STEMI) 
and non-STEMIs  (NSTEMI) from a small island de-
veloping state (SIDS).
 ► Several years of data collection allowing adequate 
power to detect important gender differences for 
STEMI and NSTEMI.
 ► Inadequate power to detect potentially important 
gender differences for unstable angina.
 ► Significant barriers to collection of data from pa-
per-based records as occurred in SIDS were 
overcome.
 ► Only 68% of notes search for were retrieved for un-
stable angina in hospital while 87% of notes in pri-
mary care for chronic angina were retrieved.
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bias or biology.10 Published treatment data are unavail-
able for Barbados and the Caribbean. Internationally, 
some studies have shown women are less likely to receive 
timely treatment in the acute period and are more likely 
to receive medical management rather than primary 
percutaneous coronary intervention (PCI)11–13 while 
others from the USA have shown no difference.7 Studies 
vary considerably in the gender differences observed in 
treatment given at discharge.11 14
Despite knowing that the level of adherence and avail-
ability of treatments is critical to reducing cardiovas-
cular mortality, we were unable to find any studies from 
the Caribbean within the past 25 years which provide 
a description of treatment used in the management of 
ACS. In this study, we examine the documented treat-
ment proportion rates for ST-segment elevated myocar-
dial infarction (STEMI) and non-STEMI (NSTEMI) 
within the first 24 hours as well as at discharge. We have 
chosen to use class 1 recommendations from the Amer-
ican College of Cardiology/American Heart Associa-
tion (ACC/AHA) Task Force on Practice Guidelines.15 
Given the gender difference noted in mortality rates, the 
main aim of this paper is to explore gender differences in 
documented prescribing practices for each ACS and eval-
uate whether patients with ACS in Barbados are treated 
with optimal medical therapy in both the hospital and 
community settings.
MethODs
study sites and design
Data for this study were obtained from two main sourc-
es—a population-based national registry, and a retrospec-
tive chart review conducted in two sites (the country’s 
lone tertiary public sector hospital and the island-wide 
government-operated primary care centres). The national 
registry provided information on proportions of patients 
prescribed specific drugs for acute MI during the first 
24 hours of symptoms and on discharge from the main 
hospital. The retrospective hospital chart review provided 
information on medications provided to patients with 
unstable angina, while the primary care section of this 
review provided data on medications prescribed for 
patients with chronic angina. Our reporting was guided 
by Strengthening the Reporting of Observational Studies 
in Epidemiology guidelines for cohort studies.16
MI: population-based data (registry)
We obtained data for the years 2009–2016 from the 
Barbados National Registry for Chronic Non-communi-
cable Disease (the BNR), the only multidisease registry 
in the Western Hemisphere.17 This national surveil-
lance system collects data from hospital and community 
records for all patients diagnosed with an acute MI, using 
a mixture of active and passive case finding.17 After MI 
events are verified, patient notes are abstracted and later 
entered into a database for analysis and dissemination. 
To accomplish its case finding, the BNR engages both 
the public and private healthcare sectors. One of the 
main sources of data is the Queen Elizabeth Hospital 
(QEH)—a 600-bed facility, the island’s lone tertiary care 
centre. Within the QEH, data are provided by the acci-
dent and emergency department, medical records and 
death records departments and the medical and surgical 
wards. Data sources outside the QEH include the poly-
clinics (government-operated primary care centres), 
private physicians, therapists, emergency centres and the 
National Register of Births and Deaths.
The BNR collects information on medications used 
acutely within the first 24 hours of onset. In addition, medi-
cations given at discharge and chronic medications used 
by the patient prior to the event are registered. Medica-
tion sources include ambulance reports; referral sheets/
letters from emergency clinics and general practitioners 
(GP) (any medications documented as having been given 
at the GP/emergency clinic before hospital admission); 
accident and emergency records sheet; nurses’ report; 
physicians’ treatment card; and the patient discharge 
note.
unstable angina in the tertiary care centre
Because the BNR does not collect data on patients 
with unstable angina, a retrospective chart review was 
conducted at the QEH. The participant population 
comprised adult residents of Barbados treated at the 
hospital for unstable angina. No limits were placed on 
race, gender or geographic locations within Barbados. 
Private sector management of ACS was not conducted 
due to lack of resources.
In the hospital review, we obtained a list of all records 
with a discharge diagnosis of unstable angina, filed using 
the International Classification of Diseases-Tenth Revi-
sion I20.0 code during years 2010–2014, which totalled 
614 patients. To estimate sample size, we assumed all drug 
proportions at 50% for the purpose of the power calcu-
lation, to produce 95% CIs of ±7.5%. We estimated we 
would require 180 notes for review but in anticipation of 
having irretrievable records we chose to sample 200.
From the list of all unstable angina records, a system-
atic (every third) sample of 200 records was requested 
from the list of all persons admitted to hospital, of which 
136 (68% response rate) notes were located. Data were 
abstracted by trained abstractors and entered into a secure 
electronic database and files encrypted. Abstracted data 
were entered into an EPI INFO database. We abstracted 
only the medications prescribed on discharge using 
physicians’ and nurses’ records contained in the patient’s 
paper-based file.
Chronic angina in polyclinics
As an assessment of community treatment, a retrospec-
tive review was conducted within the eight public primary 
care centres in Barbados to determine the proportions 
of patients with chronic angina receiving adequate treat-
ment. A records clerk used the polyclinics’ electronic 
medical database system to extract all persons who were 
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seen in the polyclinics during the period 2010–2014 with 
a diagnosis listed as ‘Ischaemic Heart Disease-Angina’ 
regardless of whether this was the main reason for the 
visit. (This is the code for angina in accordance with the 
International Primary Care Coding system.) All visits 
of each of these persons during the 5-year period were 
abstracted into an Excel spreadsheet. After duplicate 
records/visits were removed, a total of 834 unique indi-
viduals were seen in the public sector with this diagnosis 
in 2010–2014.
A sample of 272 notes were selected using simple 
random sampling (using an Excel random number 
generator) from this list and given to the data abstractor 
for retrieval. Notes were regarded as eligible if documen-
tation confirmed that patients were seen at the clinic at 
least twice for this condition in the past 12 months. Of the 
272 notes, 236 (87% response rate) were found and noted 
to be eligible for data abstraction. Records could not be 
found for two persons, who were noted to be deceased. 
Due to the difficulty in tracing medical records when 
examining unstable and chronic angina using the chart 
reviews, results may be less robust than BNR data, thus a 
greater focus is placed in analysis on acute MI data from 
the BNR. We present the unstable and chronic angina 
data, however, as the best available data from our setting.
Data analysis
Prescribed drugs were recorded and classified by 
type—statins, beta-blockers (BB), fibrinolytic drugs 
and ACE inhibitor (ACEI) or angiotensin II receptor 
blocker (ARB). We summarised categorical variables, 
including disease status and drugs prescribed, as n (%) 
and continuous variables as mean (SD). We compared 
proportions between groups using 95% CIs. We calcu-
lated the prescribed proportions by age groups (30–69 
years old and 70 years and older) and gender for drugs 
considered recommended by class 1 evidence by ACC/
AHA for post-MI and unstable angina treatment as well 
as the proportion of patients with chronic angina in the 
community by age and gender receiving prescriptions 
for aspirin, clopidogrel, statins, BB and ACEI or ARB. 
The AHA/ACC recommends aspirin (ASA), P2Y12 inhib-
itor, fibrinolytics and anticoagulation for management 
of STEMI in the first 24 hours and ASA, any P2Y12 inhib-
itor, BB, statin±ACEI or ARB on discharge. Nitrates are 
also recommended for symptomatic relief only. Since our 
interest is in the effectiveness of secondary prevention 
modalities, nitrates and anticoagulation treatment were 
not analysed.
We assessed the effects of age (measured as a contin-
uous variable) and gender on aspirin, clopidogrel, statins, 
BB, fibrinolytic drugs and ACEI or ARB using multivari-
able logistic regression. We conducted bivariate anal-
yses to explore the effects of documenting each of the 
following comorbidities (hypertension, diabetes, previous 
ischaemic heart disease, obesity, smoking, history of coro-
nary angiography, atrial fibrillation, congestive cardiac 
failure and systolic blood pressure on presentation) on 
fibrinolytic use for patients with STEMI. Using Akaike 
information criterion, the final model explaining the rela-
tionship between reperfusion and predictors of adher-
ence included age, gender, medical history of diabetes, 
hypertension and smoking. Complete adherence to 
prescribing was defined as persons discharged on all five 
recommended medications proven to reduce morbidity 
and mortality post-CHD event. For those in the commu-
nity, complete adherence to prescribing was defined as 
those on the four medications recommended for stable 
angina. Data were analysed using Stata V.13.
Patient and public engagement
Patients and the public were not actively involved in this 
study. Data from these findings have been disseminated to 
the healthcare providers and key stakeholders to facilitate 
policy and planning around care of patients with MI in 
Barbados. Dissemination targeted at the general public 
was released at a 70th Anniversary Celebration open day 
of the University of the West Indies in November 2018.
ethical considerations
This study was approved by the Institutional Review Board 
of the University of the West Indies/Ministry of Health, as 
well as the internal ethics committees of the QEH and the 
Ministry of Health (the government agency responsible 
for management of the public primary care centres). No 
information on patient identifiers was abstracted since 
participants were not followed or contacted after this 
audit.
results
For the years 2009–2016, there were 2750 patients 
identified by the BNR with a diagnosis of acute MI. Of 
these, 1589 were admitted to hospital; 1295 notes were 
completely reviewed by the registry data abstraction team 
while 294 were diagnosed based on only their death certif-
icate. For 1018, the diagnosis of acute MI was definitively 
made using ECG and cardiac enzymes. Classification of 
these patients according to type of acute MI revealed that 
45.8% (466) were diagnosed with NSTEMI and 54.2% 
(552) with STEMI (figure 1).
A higher proportion of men were diagnosed with 
STEMI compared with women: 58.8% vs 48.8%, respec-
tively (p=0.001). Women generally had significantly 
higher rates of several comorbidities (hypertension, 
diabetes and obesity). Men had significantly higher rates 
of smoking (table 1).
Documented medications prescribed in first 24 hours for 
patients with steMI/nsteMI
Overall in acute management of patients with NSTEMI 
and STEMI, documentation indicated that only two 
(aspirin and clopidogrel) of six drugs had documented 
prescription greater than 80%. Aspirin was the most 
prescribed drug: 87% (95% CI 83% to 89%) with no 
significant gender or age differences in prescribing 
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proportions, while a fibrinolytic drug was least likely to 
be prescribed, 57% (95% CI 51% to 63%) in men and 
31% (95% CI 24% to 39%) in women. Figure 2 displays 
the proportion of documented medications prescribed in 
younger (30–69 years old) and older (70 years and older) 
age groups by gender. Persons with NSTEMI had relatively 
lower prescription than STEMI, with gender significant 
differences noted for the latter. In patients with STEMI, 
after adjustment for age, men were more than twice as 
likely to receive fibrinolytics compared with women: OR 
2.38 (95% CI 1.56 to 3.63) and 45% more likely to receive 
clopidogrel: OR 1.45 (95% CI 0.87 to 2.43).
After bivariate analysis, smoking was found to be posi-
tively associated with fibrinolytic use—crude OR 2.21, 
95% CI (1.27 to 3.83). Persons with a history of diabetes 
and hypertension were less likely to receive fibrinolysis—
crude OR 0.44 (95% CI 0.27 to 0.72) and crude OR 0.59 
(95% CI 0.36 to 0.99), respectively. The most parsimo-
nious model showed that age and sex were statistically 
significant predictors of use of fibrinolytics. Patients with 
Figure 1 Numbers of eligible patients with AMI for 2009–2016 in Barbados. AMI, acute myocardial infarction; MI, myocardial 
infarction; NSTEMI, non-STEMI; STEMI, ST-segment elevated myocardial infarction.  
Table 1 Characteristics of patients with acute myocardial infarction (MI) by gender and MI classification
STEMI NSTEMI
Male (n=341) Female (n=211) Male (n=234) Female (n=236)
Mean age (95% CI) 61.9 (60.4 to 63.4) 69.1 (67.3 to 70.8) 64.5 (62.8 to 66.4) 70.0 (68.2 to 71.8)
Medical history
  Hypertension, % (95% CI) 74.9 (69.7 to 80.1) 89.7 (85.4 to 94.0) 78.9 (73.2 to 84.6) 93.9 (90.5 to 97.3)
  Refractory hypertension 
(SBP>180 mm Hg)
11.9 (8.3 to 15.4) 15.6 (10.7 to 20.5) 16.1 (11.2 to 20.9) 28.9 (22.9 to 34.9)
  Diabetes 55.6 (48.7 to 62.3) 82.6 (76.7 to 88.5) 59.3 (51.1 to 67.5) 80.5 (74.1 to 86.9)
  Angina 42.9 (32.0 to 52.8) 60.4 (46.3 to 74.5) 55.4 (42.1 to 68.6) 77.0 (66.3 to 87.8)
  Previous stroke 13.3 (6.9 to 19.6) 17.1 (8.5 to 25.7) 17.6 (8.4 to 26.9) 21.0 (12.0 to 30.0)
  Previous CABG 25.0 (12.4 to 37.6) 15.0 (0.0 to 31.4) 21.1 (1.5 to 40.6) 35.3 (11.0 to 59.5)
  Atrial fibrillation 26.2 (15.0 to 37.5) 35.3 (18.8 to 51.8) 31.2 (14.6 to 47.9) 34.3 (18.0 to 50.5)
  Prior MI 20.5 (8.2 to 32.7) 30.0 (13.0 to 47.0) 35.3 (21.9 to 48.7) 32.7 (19.7 to 45.7)
  Smoker 26.3 (21.0 to 0.1) 5.3 (1.7 to 8.9) 28.2 (21.6 to 34.8) 5.4 (2.0 to 8.9)
  Obesity 70.5 (63.5 to 77.5) 83.1 (76.4 to 89.7) 83.3 (76.4 to 90.2) 83.3 (77.1 to 89.6)
  Previous coronary angiography 10.5 (0.0 to 20.6) 0.6 (0.0 to 17.7) 18.7 (0.0 39.5) 9.0 (0.0 to 27.8)
CABG, coronary artery bypass graft; NSTEMI, non-STEMI; SBP, systolic blood pressure; STEMI, ST-segment elevated myocardial infarction. 
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STEMI were less likely (adjusted OR 0.97, 95% CI 0.95 to 
0.99) to receive fibrinolytics for every 1 year increase 
in age, while men were more likely (adjusted OR 2.28, 
95% CI 1.24 to 4.21) than women to receive fibrinolytic 
treatment after adjustment for diabetes, hypertension 
and smoking.
Persons less than 70 years old tended to have docu-
mented prescription proportions similar to those over 70 
years for clopidogrel, aspirin and BB, but the younger age 
group was prescribed more aggressive therapy in the case 
of statins and fibrinolytics. Age (modelled as a continuous 
variable) was a significant predictor for the use of fibrino-
lytics, with younger persons being more likely to receive 
this form of therapy (table 2). After adjustment for age, 
diabetes, hypertension, smoking and systolic blood pres-
sure on admission, men with STEMI were 2.34 (95% CI 
1.25 to 4.36) times more likely to be given reperfusion 
treatment than their female counterparts.
Discharge trends
Documented prescribing proportions on discharge 
ranged from 62% (95% CI 57% to 67%) for clopidogrel 
therapy to 84% (95% CI 80% to 88%) for BB treatment in 
patients with STEMI and from 72% (95% CI 66% to 78%) 
for clopidogrel to 87% (95% CI 82% to 91%) for aspirin 
in patients with NSTEMI (figure 3). Persons younger than 
70 years old had higher documented prescription rates 
for all drugs except in the case of men on BB and statins. 
Logistic regression indicated that women and younger 
persons were generally more likely to be discharged 
on recommended medications. The exception to this 
occurred for women on aspirin and BB where older 
persons had higher documented prescriptions.
Patients with angina in hospital and the community
At the QEH, for the period 2010–2014, 57.2% (78) of the 
138 patients with unstable angina were female. The mean 
Figure 2 Proportion of patients with ST-segment elevated myocardial infarction (STEMI) who received recommended 
treatment in the first 24 hours of hospital admission by age and gender. ARB, angiotensin II receptor blocker. 
Table 2 Logistic regression displaying the extent to which gender (crude and age adjusted) predicted proportions of 
medications prescribed for persons with STEMI/NSTEMI during the first 24 hours
Female (reference)
STEMI OR (95% CI) NSTEMI OR (95% CI)
Crude Adjusted Crude Adjusted
Aspirin 1.02 (0.61 to 1.72) 0.95 (0.56 to 1.63) 1.34 (0.79 to 2.27) 1.37 (0.79 to 2.35)
Clopidogrel 1.60 (0.97 to 2.63) 1.45 (0.87 to 2.43) 1.19 (0.73 to 1.94) 1.20 (0.73 to 1.97)
Beta-blockers 0.91 (0.65 to 1.27) 0.85 (0.60 to 1.20) 0.88 (0.61 to 1.26) 0.83 (0.57 to 1.20)
ACE_ARB 1.00 (0.71 to 1.42) 0.99 (0.70 to 1.42) 1.17 (0.81 to 1.69) 1.07 (0.74 to 1.57)
Statins 1.40 (0.93 to 2.10) 1.24 (0.82 to 1.90) 1.19 (0.73 to 1.94) 1.13 (0.69 to 1.86)
Fibrinolytics 2.93 (1.95 to 4.41) 2.38 (1.56 to 3.63) NA NA
ARB, angiotensin II receptor blocker; NA, not applicable; NSTEMI, non-STEMI; STEMI, ST-segment elevated myocardial infarction. 
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ages for men and women were 65.3 (SD 12.7) and 61.1 (SD 
13.5), respectively. Documented prescribing proportions for 
patients with unstable angina ranged from 57% (95% CI 
48% to 65%) (clopidogrel) to 88% (95% CI 81% to 93%) 
(aspirin). There were no significant differences by gender 
or age.
In the community, the prescribed proportions were gener-
ally lower for use of ACEI/ARBs (58% in men, 63% in 
women) and BB (52% in men and 63% in women) but rela-
tively high for statins (67% in men and 74% in women) and 
aspirin (81% in men and 77% in women). Older persons 
were more likely to be treated in all medication and gender 
groups but none of these differences reached statistical 
significance.
hospital versus community physician adherence to 
recommended medications for patients with ChD
Documented prescribing adherence to recommended medi-
cations was generally higher in hospital compared with the 
community. In persons diagnosed with STEMI, 36.4% (95% 
CI 29.8 to 0.43.5) were documented as discharged on all 
five medications recommended, while among patients with 
NSTEMI, a similar proportion was noted (35.9%; 95% CI 
30.9 to 41.2). Almost one-third of patients with unstable 
angina were discharged from hospital with all five medica-
tions recommended. This was similar in men and women: 
28.3% (95% CI 17.4% to 41.4%) vs 33.3% (95% CI 23.2% to 
44.7%), respectively. Age and gender were not significant 
predictors of complete adherence.
DIsCussIOn
When comparing gender distributions for ACS, several 
patterns emerged. Men had higher prescription propor-
tions in the first 24 hours of care for all drugs examined 
except BB, but the difference was significantly higher 
than women in the case of fibrinolytics used for reperfu-
sion therapy after adjustment for age and other comor-
bidities. This gender difference in the first 24 hours 
may explain the higher case fatality seen in women in 
Barbados. Similar findings were noted in Puerto Rico and 
Australia.18 19 The absence of primary percutaneous inter-
vention during this time period may also be a contributor 
to the relatively high case fatality rates in both sexes.
Documented prescription rates in the first 24 hours 
in Barbados were lower than those reported in USA 
and Canadian-based registries20 21 and in an analysis of 
the Australian and New Zealand cohort of the Global 
Registry of Acute Coronary Events (GRACE).22 The 
discharge prescription rates were similar: proportions 
of medications prescribed were 95%, 85% and 89% for 
aspirin, BB and statin use, respectively, in the GRACE 
study.22 In Barbados, the corresponding proportions were 
88%, 84% and 90% for persons diagnosed with STEMI. 
These proportions were higher than average medication 
uptake rates quoted for 10 low/middle-income coun-
tries (LMIC) in the WHO-Prevention of Recurrences 
of Myocardial Infarction and Stroke study,23 which were 
aspirin (81.2%), BB (48.1%) and statins (20.8%).
Barbados, along with eight other Caribbean Community 
countries, is classified by the World Bank as a high-income 
country even though its per-capita gross domestic product is 
one-third that of other similarly classified countries such as 
the USA. Barbados faces many of the vulnerabilities of being 
a small island developing state (SIDS). In a study comparing 
in-hospital trends of revascularisation and prescription of 
medications at discharge in patients with ACS from high-in-
come (Canada and USA) and LMICs (India, Iran, Pakistan 
and Tunisia), Shimony et al showed that no patients from 
Figure 3 Proportion of patients with ST-segment elevated myocardial infarction (STEMI) who received recommended 
treatment on discharge from hospital by age and gender. ARB, angiotensin II receptor blocker. 
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LMICs were treated by coronary artery bypass graft (CABG) 
surgery compared with 9.6% of patients from high-income 
countries.24 Barbados’ discharge medication uptake rates 
mirror those of developed countries but its rates for the 
costlier intervention services like CABG more closely mirror 
LMICs likely because it is a SIDS with limited resources and 
capacity for tertiary care services. The latter was reflected in 
the non-availability of primary PCI during the study period 
and may contribute to the relatively high in-hospital case 
fatality rates. An interventional cardiologist was hired in 
2016 and has begun to offer percutaneous angiography to 
patients non-acutely from 2017. There are currently insuffi-
cient resources to offer this modality acutely.
In our study, women consistently had higher prescrip-
tion proportions on discharge, particularly in the case 
of BB. Previous international studies had shown slightly 
higher prescribing among men but more recent analyses 
from the Acute Coronary Treatment and Interventions 
Outcomes Network (ACTION) Registry-Get With the 
Guidelines database obtained from US hospitals showed 
no significant difference in prescribing between men 
and women.20 The ACTION Registry database is derived 
from data received on consecutive patients admitted with 
acute MI, either STEMI or NSTEMI, from more than 450 
participating hospitals across the USA.25
Limitations on data interpretation should be acknowl-
edged as the analysed sample of patients with unstable 
angina in particular was relatively small. We did not 
retrieve the required sample size for the retrospective 
chart review, thus limiting our power. There may also have 
been selection bias since several of the records requested 
could not be found. This is most likely to be a problem 
for the review of patients with unstable angina where our 
response rate was only 68%. The BNR is an attempt at full 
enumeration of all cases of acute MI in the island but, 
as noted in figure 1, notes are less likely to be retrieved 
by BNR data abstractors when the person is deceased. 
These are more likely to be the severe cases, and so our 
estimates may be reflective of management for less severe 
acute MI in Barbados.
Data abstraction was being done through the perusal 
of paper records, which may present several barriers 
to detecting and accurately documenting medications 
that have been given. Potential barriers to good data 
abstraction include poor handwriting of physicians and 
nurses, poorly assembled notes and omissions of relevant 
details. As this was retrospective data collection, the data 
being documented were not specifically written for the 
purposes of this or any study and thus documentation was 
often inconsistent.
COnClusIOn
Studies documenting prescription patterns are not 
common among SIDS and thus modelled estimates based 
on assumptions from developed countries are often used 
as proxies.26 We found significant gender disparity in rates 
of fibrinolytics prescribed in Barbados. Less than 60% 
of men and approximately one-third of women receive 
reperfusion using medical thrombolysis. This analysis is 
particularly important for Caribbean policymakers since 
using data from other dissimilar territories can lead to 
overestimation or underestimation of the effects of inter-
ventions. Previous studies from LMICs have had small 
sample sizes, our findings fill a significant gap in the liter-
ature that exists for LMICs and SIDS in particular.
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